Overview
ERNA market data
Price History
ERNA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$55.83 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.55 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 40.8% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.18 – $71.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $4.9 · P/B 3.92 · P/S 8.42.
Company news
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell TherapyBenzinga · Jul 15, 2026, 6:11 PM
Ernexa Therapeutics shares are trading higher after the company announced new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA-101, in combination with PD-1 checkpoint inhibition.Benzinga · Jul 15, 2026, 2:09 PM
Dow Gains Over 150 Points; Morgan Stanley Profit Tops ViewsBenzinga · Jul 15, 2026, 1:43 PM
Ernexa Therapeutics Announces Independently Conducted Study Validating Anti-Tumor Activity Of Its ERNA-101 Lead Cell Therapy Candidate Shows Complete Tumor Clearance, Durable Long-Term Survival; Investigational New Drug Submission Planned In Q3Benzinga · Jul 15, 2026, 11:53 AM
Ernexa Therapeutics Advances ERNA-101 Toward IND Filing In Q3 2026; Targeting Phase 1 Cancer Trial Initiation In Q4 2026Benzinga · Jun 17, 2026, 12:50 PM
Ernexa Therapeutics Announces Progress In Development Of ERNA-101; Hits Multiple Milestones Ahead Of Planned IND Submission In Q3 2026 And First‑In‑Human Study InitiationBenzinga · May 27, 2026, 12:13 PM
Ernexa Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 40.48%Benzinga · May 15, 2026, 4:54 PM
Ernexa Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 56.07%Benzinga · May 15, 2026, 4:49 PM
Ernexa Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 39.96%Benzinga · May 15, 2026, 4:44 PM
Ernexa Stock Is Jumping Today: What's Going On?Benzinga · May 12, 2026, 7:25 PM